Int. J. Med. Sci. 2010, 7 http://www.medsci.org 309 IInntteerrnnaattiioonnaall JJoouurrnnaall ooff MMeeddiiccaall SScciieenncceess 2010; 7(5):309-313 © Ivyspring International Publisher. All rights reserved Research Paper Clinical Strategy for the Management of Solid Pseudopapillary Tumor of the Pancreas: Aggressive or Less? Hong Chang1, Yi Gong2, Jian Xu1, Zhongxue Su1, Chengkun Qin1, Zhenhai Zhang1 1. Department of General Surgery, Shandong Provincial Hospital affiliated to Shandong University, Jinan Shandong, China; 2. Department of Rehabilitation, Shandong Provincial Hospital affiliated to Shandong University, Jinan Shandong, China. Corresponding author: Hong Chang, Department of General Surgery, Shandong Provincial Hospital, Shandong Univer -sity, 324, Jing5Wei7 Road, Jinan Shandong, China. Tel: 531-85186363. Email: changhong@sdu.edu.cn Received: 2010.05.14; Accepted: 2010.08.27; Published: 2010.09.01 Abstract Objective: To further delineate the clinicopathological and radiological features of solid pseudopapillary tumor (SPT) of the pancreas and s u m m a r i z e t h e s u r g i c a l t h e r a p y s t r a t e g y f o r t h i s t u m o r . M e t h o d s : A r e t r o s p e c t i v e r e v i e w o f 1 8 p a t h o l o g i c a l l y c o n f i r m e d c a s e s o f S P T w a s performed and the clinical and pathological features, radiological findings and surgical inter-ventions were analyzed. Results: The patients included 17 females and 1 male with a median age of 23 years. The median diameter of the lesions was 8.0 cm. Abdominal pain was the predominant complaint (8/18). The rest of the patients were asymptomatic and presented with a pancreatic mass detected incidentally. Radiological study revealed a well-demarcated mass which was composed of a solid-cystic portion. On post-contrast CT, the solid portions could be enhanced whereas the cystic parts remained unenhanced. With the preoperative diagnosis of SPT in 11 patients and pancreatic cyst, benign or malignant pancreatic tumor in the rest, pancreatic tumor resection was successfully completed. Surgical exploration findings, pathological characteristics and good prognosis of the patients with SPT, indicated its low-grade malignant potential. Conclusion: In combination with clinical findings, radiological features of SPT may help to make the correct diagnosis and differentiation from other pan-creatic neoplasms. Once diagnosed, given the excellent prognosis and low-grade malignancy, less aggressive surgical resection of the primary lesion is proposed. Key words: Diagnosis, Pancreas, Solid pseudopapillary tumor, Surgery Introduction Solid Pseudopapillary T um o r (SPT) of the pan-creas is a very rare entity with a reported incidence of 0.13% to 2.7% of all pancreatic tumors,1 whi ch w as once described in many other terms, such as Frantz’s tumor, solid and cystic tumor, papillary cy st ic neop -lasm, a n d solid and papillary epithelial neo p l a s m .2 From 1996, the term of SPT was recommended by the WHO pancreatic working group a nd is being widely accepted in medical p ra ct ice .3 Of note, in recent re-ports it has been concluded gradually that Solid Pseudopapillary Neoplasm of the pancreas (SPN) is the correct description regarding the terminology.4,5,6 Despite the increases in recognition of characteristics of this tumor, which include Form C: Content of Commitment for Letter/E-mail October 00, 2XXX Subject: Letter of Commitment to be a Co-Investigator Dear JICA Project for AUN/SEED-Net, It is my great pleasure to be a co-investigator of the proposal for Collaborative Research Program for Common Regional Issues (CRC) or Collaborative Research Program with Industry (CRI) 2018 with the title “ (research title) _” submitted by (Academic title and name of Principal Investigator) I very much support and contribute to the research project Sincerely Yours, (Academic title and name) ((Position)) ((Department)) ((University)) ((address)) Complex transcriptional and translational regulation of iPLA 2 c resulting in multiple gene products containing dual competing sites for mitochondrial or peroxisomal localization David J. Mancuso 1,2 , Christopher M. Jenkins 1,2 , Harold F. Sims 1,2 , Joshua M. Cohen 1,2 , Jingyue Yang 1,2 and Richard W. Gross 1,2,3,4 1 Division of Bioorganic Chemistry and Molecular Pharmacology, and Departments of 2 Medicine, 3 Chemistry and 4 Molecular Biology and Pharmacology, Washington University School of Medicine, St. Louis, MO, USA Membrane-associated calcium-independent phospholipase A 2 c (iP LA 2 c) contains four potential in-frame methionine start s ites (Mancuso, D.J. Je nkins, C .M. & Gross, R.W. (2000) J. Biol. Chem. 275, 9937–9945), but the mechanisms regulating the types, amount and subcellular localization of iPLA 2 c in cells are i ncompletely understood. We now: (a) demonstrate the dramatic transcriptional repression of mRNA synthesis encoding iPLA 2 c by a nucleotide sequence nested in the coding sequence itself; (b) localize the site of transcriptional repression to the most 5¢ sequence encoding the iPLA 2 c holoprotein; (c) identify the presence of nuclear protein c onstituents w hich bind to the repressor region by gel shift analysis; (d) demonstrate the translational regulation of distinct iPLA 2 c isoforms; (e) identify multiple novel exons, promoters, and alternative splice variants o f human iPLA 2 c; (f) document the presence of dual-competing subcellular localization s ignals in discrete isoforms of iPLA 2 c;and (g) demonstrate t he functional integrity of an N-terminal mitochondrial localization signal by fluorescen ce imagi ng and the presence of iPLA 2 c in the mitochondrial compart- ment of rat myocardium. The intricacy of the r egulatory mechanisms of iPLA 2 c biosynthesis in rat myocardium is underscored by the identification of seven distinct protein products that utilize multiple mechanisms (transcription, translation and proteolysis) to produce discrete iPLA 2 c polypeptides containing either single or dual subcellular localization s ignals. T his unanticipated complex i nterplay between peroxisomes and mitochondria mediated by com- petition for uptake of the nascent iPLA 2 c polypeptide identifies a new level of phospholipase-mediated m etabolic regulation. Because uncoupling protein function is regulated by free fatty acids in mitochondria, these results suggest that iPLA 2 c processing contributes to integrating respiration a nd thermogenesis in mitochondria. Keywords: phospholipase; mitochondria; p eroxisomes; tran- scription; translation. Phospholipases A 2 (PLA 2 s) play critical roles in cellular growth, lipid homeostasis and lipid second messenger generation by catalyzing the esterolytic cleavage of the sn-2 fatty acid o f glycerophospholipids [1–5]. The resultant fatty acids and lysolipids are potent lipid mediators of signal transduction and a lter the biophysical properties o f the membrane bilayer, collectively contributing t o the critic al roles that phospholipases play in cellular adaptation, proliferation and signaling. PLA 2 s constitute a d iverse family of enzymes, which include the intracellular phos- pholipase families, cytosolic PLA 2 s(cPLA 2 ) and calcium- independent PLA 2 s(iPLA 2 ) as well as the secretory PLA 2 s (sPLA 2 ). More than a decade ago, we identified multiple types of kinetically distinguishable iPLA 2 activities in the cytosolic, microsomal and mitochondrial fractions from multiple species 9 Standard Form of Agreement for Design Services AIGA | the professional association for design AIGA | the professional association for design 164 Fifth Avenue, New York, NY 10010 212 807 1990, www.aiga.org AIGA Board: Bill Grant, president; Shel Perkins, secretary-treasurer; Richard Grefé, executive director; James Ales, Connie Birdsall, Laurie Churchman, Moira Cullen, David Gibson, Steve Hartman, Marcia Lausen, Debbie Millman, Marty Neumeier, Bennett Peji, Hank Richardson, Mark Randall and Bonnie Siegler; Michael Hodgson, Publisher: Richard Grefé, AIGA Editorial content: Jim Faris and Shel Perkins Design: Grant Design Collaborative, Atlanta Fonts: Interstate and Filosofi a Copyright: © AIGA 2007. The fi rst edition was published in 2005. Disclaimer: Legal Information Is Not Legal Advice. This publication provides information about the law designed to help designers safely cope with their own legal needs. But legal information is not the same as legal advice — the application of law to an individual’s specifi c circumstances. Although AIGA goes to great lengths to make sure our information is accurate and useful, we rec- ommend that you consult a lawyer if you want professional assurance that our information, and your interpretation of it, is appropriate to your particular situation. Presenting Sponsor for the AIGA Design Business and Ethics series: Paper Sponsor for the AIGA Design Business and Ethics series: Printing Sponsor for the AIGA Design Business and Ethics series: www.apdf.org Endorsed by www.adobe.com www.peakedelancey.com www.domtarearthchoice.com 1 Table of contents Introduction: AIGA Standard Form of Agreement 3 Basic terms and conditions 27 Schedule A: Intellectual Property Provisions 39 Supplement 1: Print-Specifi c Terms and Conditions 43 Supplement 2: Interactive-Specifi c and Terms & Conditions 45 Supplement 3: Environmental-Specifi c and Terms & Conditions 47 Page intentionally left blank. 3 Introduction: AIGA Standard Form of Agreement Welcome to the latest version of the AIGA Standard Form of Agreement for Design Services . If you’re familiar with the previous versions, you’ll notice that this one is quite different. It does not take a one-size-fi ts-all approach, and it is not an extensive pre-printed document where you simply fi ll in the blanks. Instead, it acknowledges that most design fi rms develop their own custom proposal document for each project and are looking for an appropriate set of terms and conditions to attach to it. When put together and signed, the custom proposal document and its attached terms and conditions comprise the binding agreement with the client. With this in mind, the new focus of the AIGA Standard Form of Agreement is on those terms and conditions. AIGA members are involved in many different design disciplines. Because of this, the recommended terms and conditions have been prepared in a modular format. This also helps to keep individual agreements down to a more manageable size. The fi rst two modules, Basic Terms and Conditions and Intellectual Property Provisions, should be used for all design assignments. An Original article Application of deltamethrin for spraying or dipping to protect Scots pine seedlings against Hylobius abietis L and logs against Tomicus piniperda L B Glowacka A Lech, W Wilczynski Forest Research Institute, Wery-Kostrzewy 2, 00-973 Warsaw, Box 61, Poland (Received 9 January 1990; accepted 28 September 1990) Summary — The authors compared the efficiency of protecting Scots pine trees against Hylobius abietis L, the large pine weevil, using deltamethrin (Decis 2.5 EC) by dipping seedlings before plant- ing and by spraying after planting. Assessment of damage caused by the beetles and the rate of degradation of the insecticide on the plants proved that dipped seedlings were less frequently dam- aged and were protected by 10 times the quantity of active insecticide ingredient than sprayed plants. Experiments were also carried out to analyse the application of deltamethrin in the protection of wood before bark stripping against Tomicus piniperda L, the pine-shoot beetle. Treatments were carried out after the last frosts in the early spring and during the first days of swarming. Analysis of infested wood and the degradation of the deltamethrin in the bark showed a high degree of insecti- cide persistence and thus the possibility of efficient protective treatment 2-3 wk before the swarming period. Hylobius abietis / Tomicus piniperda / Pinus sylvestris / deltamethrin Résumé — Application de deltaméthrine pour la protection des jeunes pins sylvestres contre l’hylobe du pin, Hylob ius abietis L et celle des bois coupés contre l’hylesine du pin, Tomicus piniperda L. On a comparé l’efficacité de la deltaméthrine sur des plants de pin sylvestre contre l’hy- lobe, Hylobius abietis L. La deltaméthrine, Decis 2.5 EC a été appliquée par trempage des plants avant la plantation ou pulvérisée en forêt après la plantation. On a ensuite évalué les dégâts causés par les adultes et la dégradation dans le temps de l’insecticide sur les plants. Les plants trempés dans la solution de deltaméthrine à 0,025% étaient moins fréquemment endommagés et contenaient 10 fois plus de matière active insecticide que les plants pulvérisés. Des essais d’application de delta- méthrine ont aussi été réalisés pour protéger le bois de pin non écorcé contre l’hylesine du pin, To- micus piniperda L. Le traitement était fait au début du printemps après les gelées et au début de la période d’essaimage des insectes. Le nombre d’insectes trouvés sur le bois pulvérisé et la quantité de deltaméthrine retrouvée dans l’écorce prouvent une grande persistance de l’insecticide et la pos- sibilité de traiter le bois efficacement 2-3 semaines avant la période d’essaimage. hylobius abietis / Tomicus piniperda /Pinus sylvestris / deltamethrine * Correspondence and reprints INTRODUCTION Decis 2.5 EC is mainly used in Poland for forest protection against leaf eating larvae, bark beetles and large pine weevils. In 1983, during the Lymantria monacha L nun moth outbreak, 78.2 t of Decis were applied. 18.7 27.7, 9.3 and 13.1 t of the product were used respectively during the 1984-1987 period. The exact quantity of Decis used in 1988 is not yet known but will probably be high due to outbreaks of the Panolis flammea Schiff pine beauty moth and the Bupalus piniarius L pine looper which required the product to be used over 180 000 and 30 000 ha respec- tively. Deltamethrin is used at doses of 2.5-6 g of active ingredient per ha in the control of leaf eating larvae, especially GIẤY ỦY QUYỀN GIAO DỊCH NGÂN HÀNG Kính gửi: Ngân Hàng Tôi tên: CMND/Hộ chiếu số: Ngày cấp: Nơi cấp: Địa chỉ thường trú: Là chủ tài khoản của hộ kinh doanh Giấy phép ĐKKD số: Ngày cấp: Nơi cấp: Là chủ (các) tài khoản thanh toán, thẻ tiết kiệm, chứng chỉ vàng, kỳ phiếu số: 1/ 3/ 2/ 4/ Mở tại Ngân hàng Tôi đồng ý ủy quyền cho: Ông/Bà: CMND/Hộ chiếu số: Ngày cấp: Nơi cấp: . Địa chỉ thường trú: Được sử dụng (các) tài khoản thanh toán, thẻ tiết kiệm, chứng chỉ vàng, kỳ phiếu nói trên của tôi trong phạm vi ủy quyền sau: A. ĐỐI VỚI TÀI KHOẢN THANH TOÁN 1. [ ] Được quyền sử dụng với số tiền tối đa cho từng lần giao dịch là: 2. [ ] Được quyền phát hành séc với số tiền tối đa cho từng lần giao dịch là: 3. [ ] Nội dung ủy quyền khác: Thời hạn: Từ ngày: đến ngày Từ ngày: đến khi có văn bản khác thay thế. B. ĐỐI VỚI THẺ TIẾT KIỆM, CHỨNG CHỈ VÀNG, KỲ PHIẾU 1. [ ] Được rút gốc 2. [ ] Chỉ được rút lãi 3. [ ] Được rút gốc và lãi Thời hạn: Từ ngày: đến ngày Từ ngày: đến khi có văn bản khác thay thế. Chúng tôi cam kết chịu trách nhiệm trước pháp luật về việc ủy quyền này và xác nhận ngân hàng không chịu trách nhiệm nếu có việc tranh chấp giữa Bên ủy quyền và Bên được ủy quyền. Lưu ý: 1. Bên ủy quyền và (hoặc) Bên được ủy quyền có trách nhiệm thông báo ngay cho Ngân hàng biết khi xảy ra trường hợp chấm dứt việc ủy quyền trước thời hạn. 2. Việc hết hiệu lực của Giấy ủy quyền này không làm chấm dứt trách nhiệm của Bên ủy quyền đối với các cam kết, giao dịch do Bên được ủy quyền đã xác lập với ngân hàng. Ngày tháng năm …………… Người được ủy quyền (Ký và ghi rõ họ tên) Người ủy quyền (Ký và ghi rõ họ tên) Xác nhận Ngân hàng Kiểm soát Trưởng phòng nghiệp vụ (Ký và ghi rõ họ tên) (Ký và ghi rõ họ tên) Ghi chú : Đánh d ấu [X] v ào ô 1,2,3 dành s ẵn ở nội dung cần ủy quyền v à g ạch b ỏ nh ững nội dung không ủy quy ề n. GIẤY ỦY QUYỀN / LETTER OF AUTHORIZATION V/v giao, nhận chứng từ / Delivering and receiving payment document TP Hồ Chí Minh, dated ……………………… - Căn Bộ Luật Dân Sự nước Cộng Hòa Xã Hội Chủ Nghĩa Việt Nam ban hành năm 2005 Pursuant to the Civil Code of the Socialist Republic of Vietnam issued on 2005 - Căn vào văn pháp luật hành Pursuant to current Laws I BÊN ỦY QUYỀN/Mandator (“hereinafter referred to as “We”) Họ tên: …………………………………………………………… Full Name Số Hộ chiếu/ CMND: …………………………………………………………… Passport/ ID Number Ngày cấp / Dated: ……………………… Nơicấp / Issued at:………………… Quốc tịch: …………………………………………………………… Nationality Địa thường trú: …………………………………………………………… Permanent Address Địa thư điện tử: …………………………………………………………… E-mail Address Là chủ tài khoản số: …………………………………………………………… Being the owner of Account Number(s) …………………………………………………………… II/ Bên ủy quyền (Bên B)/ Authorized Party (hereinafter referred to as “Party B”): CÔNG TY CHỨNG KHOÁN / Securities Company …………………………………………… Người đại diện / Representative: ………………………………………………………………………… Chức vụ / Position: ………………………………………………………………………………………… Địa chỉ/ Address:………………………………………………………………………………… Điện thoại/ Phone Number:……………………………………………………………………… Số Fax/ Fax Number:……………………………………………………………………………… III/ Nội dung ủy quyền/ Content of Authorization: - Bên A ủy quyền cho Bên B thực việc giao, nhận giấy tờ toán giao dịch liên quan đến tài khoản tiền gửi bên A mở Chi nhánh Ngân hàng TMCP Đầu tư Phát triển Việt Nam / Party A authorizes Party B to deliver and receive all payment documents related to Party A’s accounts opened at all branches of the Bank for Investment and Development of Vietnam JSC (BIDV) - Bên B ủy quyền lại cho nhân viên bên B để thực nội dung ủy quyền nêu / Party B’s staffs are allowed to conduct above authorization contents - Bên B có trách nhiệm thông báo danh sách nhân viên thực nội dung cho Chi nhánh Ngân hàng TMCP Đầu tư Phát triển Nam Kỳ Khởi Nghĩa / Party B has to inform BIDV - Nam Ky Khoi Nghia branch of specific staffs to conduct above authorization contents IV/ Thời hạn